This article is more than 5 years old. Information may no longer be current.

Ocular Therapeutix reports net loss of $28.7 million in 2014

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Ocular Therapeutix reported a net loss of $28.7 million, or $2.69 per share, in 2014 compared with $13.3 million, or $5.11 per share, in 2013, according to a press release.

Fourth quarter 2014 net loss totaled $8 million, or $0.37 per share, compared with $3.5 million, or $1.32 per share, in the same quarter in 2013.

The company generated $0.5 million in revenue in the fourth quarter from collaboration revenue from feasibility agreements with pharmaceutical company partners and revenue from ReSure sealant sales. Yearly revenue was $0.77 million. Revenue was not reported in 2013.

Operating expenses totaled $8 million in the fourth quarter compared with $3.4 million in the same quarter of 2013. The increase was attributed to clinical trial activities, the expansion of product development programs and costs incurred with operating as a public company.